Dimensional Fund Advisors LP decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,236,691 shares of the biotechnology company’s stock after selling 10,204 shares during the period. Dimensional Fund Advisors LP owned 0.41% of Exelixis worth $21,913,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of EXEL. Polaris Greystone Financial Group LLC purchased a new position in Exelixis during the 3rd quarter valued at about $177,000. Fox Run Management L.L.C. purchased a new position in Exelixis during the 3rd quarter valued at about $183,000. Advisors Asset Management Inc. increased its position in Exelixis by 94.7% during the 2nd quarter. Advisors Asset Management Inc. now owns 41,168 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 20,025 shares during the period. Regentatlantic Capital LLC purchased a new position in Exelixis during the 3rd quarter valued at about $249,000. Finally, Centaurus Financial Inc. purchased a new position in Exelixis during the 2nd quarter valued at about $300,000. 77.22% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently issued reports on the stock. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Wednesday. ValuEngine raised shares of Exelixis from a “sell” rating to a “hold” rating in a research report on Wednesday. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, December 17th. Piper Jaffray Companies cut their price objective on shares of Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, November 5th. Finally, Oppenheimer set a $40.00 price objective on shares of Exelixis and gave the stock a “buy” rating in a research report on Thursday, November 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $28.38.
Shares of Exelixis stock opened at $23.76 on Friday. The company has a market capitalization of $7.08 billion, a PE ratio of 46.59, a PEG ratio of 1.46 and a beta of 2.09. Exelixis, Inc. has a 52-week low of $13.42 and a 52-week high of $31.79. The company has a current ratio of 8.66, a quick ratio of 8.54 and a debt-to-equity ratio of 0.01.
Exelixis (NASDAQ:EXEL) last released its earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.22. The company had revenue of $225.40 million for the quarter, compared to the consensus estimate of $174.14 million. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. Exelixis’s revenue was up 47.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 EPS. On average, equities research analysts expect that Exelixis, Inc. will post 1.3 earnings per share for the current fiscal year.
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Recommended Story: What impact do institutional investors have on markets?
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.